Document:

EX-10.6

 EXHIBIT 10.6 
  

 
 GRANT NOTICE 

 
 Special Retention Stock Units

 [recipient name] 
 You have been granted
Special Retention Stock Units (SUs) of First Horizon National Corporation (FHNC) as follows: 
  

							
	GRANT DATE:	 	                    
, 2016	  	GOVERNING PLAN:	 	Equity Compensation Plan
	NUMBER OF SUS GRANTED:	 	 	  	PERFORMANCE PERIOD:	 	Grant Date through [7 years after grant]
	VESTING DATE OF SUS:	 	 May 12, 2023

if performance goal is met
	  	PAYMENT DATE OF SUS:	 	May 12, 2023 or shortly thereafter, if vesting occurs

 This SU award is granted under Section 10 of the Governing Plan, and is governed by the terms and conditions of that Plan
and by policies, practices, and procedures (“Procedures”) of the Compensation Committee (that administers the Plan) that are in effect during the performance and vesting periods. Also, this award is subject to the terms and restrictions of
FHNC’s stock ownership guidelines and Compensation Recovery Policy (“Policy”) as in effect during the vesting period; amendments after the Grant Date may apply to this award. 

SUs that have not been forfeited prior to the Vesting Date will have met the performance requirement of this award if the performance goal is achieved during
the Performance Period, all as set forth in Exhibit A to this Notice. Performance for this award in Exhibit A is based on achievement of a specified level of total shareholder return during the Performance Period. SUs that do not perform by the
Vesting Date automatically are forfeited on the Vesting Date. 
 This award also is subject to possible reduction or forfeiture in advance of vesting in
accordance with the Governing Plan, the Procedures, and the Policy. As of the Grant Date, the Procedures provide (among other things) that: (a) forfeiture generally will occur immediately upon termination of employment — you must remain
continuously employed by FHNC or one of its subsidiaries through the close of business on the Vesting Date; but (b) if your termination of employment occurs because of your death, permanent disability, or approved retirement (normal or early),
the SUs generally will be forfeited pro-rata in proportion to the part of the Performance Period during which you are not employed. In the case of retirement: retirement treatment must be approved by the Committee; the Committee may impose
conditions to receiving such treatment; and the Committee may deviate from pro-rationing treatment. The Committee’s general requirements to approve retirement are described in the Procedures. The Committee or its delegate will document death or
determine whether disability or retirement status has been achieved and apply pro-rationing. SUs may be suspended pending any such determinations and approvals. In any of those cases in (b), the non-forfeited SUs will vest or not vest based on
achievement of the performance goal over the entire Performance Period. 
 Other forfeiture provisions apply to this award. Currently the Plan and Policy
provide for forfeiture of SUs or recovery of SU proceeds if you engage in certain types of misconduct or if performance data is materially false or misleading and you are substantially responsible for its accuracy. In addition, this award is subject
to forfeiture or recovery to the extent required by applicable capital conservation rules or other regulatory requirements. Also, this award will be forfeited, or if already vested you must pay in cash to FHNC the gross pre-tax value of this award
measured at vesting, if during the restriction period applicable to this award: (1) you are terminated for Cause as defined in the Governing Plan; or (2) you, either on your own behalf or on behalf of any other person or entity, in any
manner directly or indirectly solicit, hire, or encourage any person who is then an employee or customer of FHNC or any and all of its subsidiaries or affiliates to leave the employment of, or to end, diminish, or move any of his, her, or its
accounts or relationships with, FHNC or any and all of its subsidiaries or affiliates. The restriction period for this award begins on the Grant Date and ends on the second anniversary of the Vesting Date. By accepting this SU award, you acknowledge
that FHNC may reduce or offset other amounts owed to you, including but not limited to wages, bonuses, or commissions owed, among other things, to satisfy any repayment obligation. 

SUs are not shares of stock, have no voting rights, and are not transferable. Each SU that vests and is paid will result in one share of FHNC common stock
being issued to you, subject to withholding for taxes, as provided below. Subject to provisions of the Governing Plan, the Committee may choose to pay all or a portion of vested SUs in cash, based on the Fair Market Value of FHNC common stock on the
Vesting Date. SUs will accrue cash dividend equivalents to the extent cash dividends are paid on common shares prior to the Payment Date. From the Grant Date until the Payment Date, dividend equivalents accumulate (without interest) as if each SU
were an outstanding share. To the extent that SUs are paid, the accumulated dividend equivalents associated with those SUs (accrued through the Payment Date) will be paid in cash as provided below. Dividend equivalents associated with forfeited SUs
likewise are forfeited. Stock splits and stock dividends will result in a proportionate adjustment to the number of SUs as provided in the Plan and Procedures. If within two years after vesting FHNC discovers an

 
error in any amount paid which, had it been known, would have resulted in a change in the amount paid of 5% or more: if the error favored FHNC, FHNC will pay you the difference in shares, subject
to applicable taxes; or, if the error favored you, FHNC will reduce your shares and dividend equivalents by an amount equal to the pre-tax difference. 

This award is not vested until the performance and service requirements both are fulfilled. Performance vesting will occur when the Committee makes a final
determination that the performance goal of this award has been achieved during the Performance Period, as provided above and in Exhibit A. Service vesting – fulfillment of the requirement that you remain continuously employed with FHNC –
will occur on the Vesting Date. 
 Vesting may be accelerated by the Committee as provided in the Governing Plan. If vesting has occurred or is accelerated,
payment may be accelerated by the Committee. 
 Unlike your regular annual performance stock unit award for 2016, this award has no mandatory post-vesting
deferral period other than a possible minor delay for administrative processing. 
 Certain Change in Control events (as defined in the Governing Plan) may
result in the forfeiture of this award or substantive changes as provided in Exhibit A. 
 Vesting and payment each are taxable events for you. Your
withholding and other taxes will depend upon FHNC’s stock value on the Vesting Date and the amount of dividends and equivalents paid to you. As of the Grant Date, the Committee’s Procedures provide that: at vesting you are required to pay
FHNC withholding taxes that are due, and you agree that FHNC may withhold the appropriate amounts from salary and other cash compensation otherwise payable to you; and, at payment, FHNC will withhold shares and cash in the amount necessary to cover
your required withholding taxes. However, the Procedures may be changed at any time. You are not permitted to make any election in accordance with Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in your gross income
for federal income tax purposes the value of the SUs this year. If you make a Section 83(b) election, it will result in the forfeiture of your SUs. FHNC reserves the right to defer payment of SUs if that payment would result in a loss of tax
deductibility. 
 Questions about your SU award? 

Important information concerning the Governing Plan and this SU award is contained in a prospectus. Copies of the current prospectus (including all applicable
supplements) are delivered separately, and you may request a copy of the Plan or prospectus at any time. If you have questions about your award or need a copy of the Governing Plan, the related prospectus, or the current Procedures, contact Fidelity
Investment’s Executive Relationship Officer at             . For all your personal stock incentive information, you may view your award and other information on Fidelity’s
website at
                                        .EX-10.2

 Exhibit 10.2 

AGREEMENT 
 THIS
AGREEMENT, dated January 8, 2016, is by and between Baxter International Inc., a corporation organized under the laws of Delaware, United States of America (“Baxter”) and Baxalta Incorporated, a corporation organized under the
laws of Delaware, United States of America (“Baxalta” and, together with Baxter, the “Parties”). 

RECITALS 
 WHEREAS, Baxter
has separated into two companies (the “Separation”): (i) one comprising Baxter’s BioScience operating segment, excluding the BioSurgery franchise, which is owned and conducted, directly or indirectly, by Baxalta, and
(ii) one comprising the Medical Products Business, including the BioSurgery franchise, which continues to be owned and conducted, directly or indirectly, by Baxter; 

WHEREAS, Baxter and Baxalta executed that certain Separation and Distribution Agreement, dated as of June 30, 2015 (as may be amended
from time to time, the “Separation and Distribution Agreement”), to govern the overall terms of the Separation; 
 WHEREAS,
in connection with the Separation, certain transactions had to be deferred until after the Distribution Date (as defined in the Separation and Distribution Agreement) and in connection with same, Baxalta World Trade LLC, Baxalta GmbH, Baxalta
Holding B.V., Baxter World Trade Corporation, Baxter Healthcare SA and Baxter Holding B.V., entered into that certain International Commercial Operations Agreement dated as of June 30, 2015 (the “ICOA”); and 

WHEREAS, in furtherance of the Separation, Baxter and Baxalta now desire to document and clarify the terms of reimbursement related to the
capitalization of certain Baxalta Local Entities (as defined in the ICOA) by Baxter or one of its Affiliates, the transfer of intercompany Accounts Receivables and Accounts Payables (as such terms are defined in the ICOA) in connection with a Local
Closing (as such term is defined in the ICOA) and the terms upon which payments shall be made between the Parties or their respective Affiliates. 

NOW, THEREFORE, in consideration of the premises and mutual covenants, agreements and provisions herein contained, and intending to be legally
bound, the Parties agree as follows: 
  

	1.	Definitions. Reference is made to Section 9.15 of the Separation and Distribution Agreement regarding the interpretation of certain words and phrases used in this Agreement. Capitalized terms used
herein but not otherwise defined herein shall have the meanings set forth in the Separation and Distribution Agreement. 

  

	2.	Capital Reimbursements; Negative Net Asset Cash Payment Reimbursements.  

  

	 	(a)	 Baxalta shall, or shall cause a Baxalta Subsidiary to, reimburse Baxter or a Baxter Subsidiary designated by
Baxter for all (i) capital infusions in excess of 50,000 United States Dollars (“Dollars”) (or the foreign currency equivalent determined applying the Exchange Rate (as defined in the ICOA) in effect on the date of the
applicable capital infusion) made by Baxter or a Baxter Subsidiary after the Effective 

  
 1 

	 	
Time to an individual Baxalta Local Entity, including any capital infusions sent on behalf of Baxalta or a Baxalta Subsidiary (each, a “Capital Reimbursement”) and
(ii) amounts of cash in excess of 50,000 Dollars (or the foreign currency equivalent determined applying the Exchange Rate in effect on the date of the applicable transfer) transferred by or on behalf of a Baxter Local Entity to a Baxalta Local
Entity as part of a Local Closing resulting from the value of the Liabilities of the applicable Deferred Baxalta Local Business exceeding the Assets of such Deferred Baxalta Local Business (each, a “Negative Net Asset Cash
Payment”). 

  

	 	(b)	Each Capital Reimbursement shall be paid by Baxalta or a Baxalta Subsidiary no later than sixty (60) calendar days following (i) the date on which Baxter or a Baxter Subsidiary makes the applicable capital
infusion into a Baxalta Local Entity or (ii) the date of this Agreement for all capital infusions made by Baxter or a Baxter Subsidiary into a Baxalta Local Entity following the Effective Time but prior to the date of this Agreement.

  

	 	(c)	Each Negative Net Asset Cash Payment shall be paid by Baxalta or a Baxalta Subsidiary no later than sixty (60) calendar days following the date on which the Negative Net Asset Cash Payment is made by or on behalf
of a Baxter Local Entity to the applicable Baxalta Local Entity. 

  

	 	(d)	Capital Reimbursement payments made by Baxalta or a Baxalta Subsidiary to Baxter or a Baxter Subsidiary shall be paid in the same currency originally used by Baxter or a Baxter Subsidiary to fund the applicable Baxalta
Local Entity. Negative Net Asset Cash Payment amounts paid by Baxalta or a Baxalta Subsidiary to Baxter or a Baxter Subsidiary shall be paid in Dollars or Euros converting the applicable foreign currency amount to Dollars or Euros applying the
Exchange Rate in effect on the date of the applicable transfer. The Parties agree that all Liabilities incurred in connection with foreign exchange risks related to each Capital Reimbursement and each Negative Net Asset Cash Payment shall be borne
solely by Baxalta. 

  

	3.	Intercompany Accounts Receivables and Accounts Payables.  

  

	 	(a)	The Parties hereby agree that the aggregate value of all accounts, notes and other receivables (net of any provision for doubtful debts recorded at the Effective Time) resulting from sales of Baxalta Products or
services prior to any Local Closing (as defined in the ICOA), whether current or noncurrent, whether resulting from sales or services prior to or after the Effective Time, whether owed by a Third Party or Baxter (or one of its Affiliates) and any
interest on such receivables (“Accounts Receivable”) are intended to be Baxalta Assets pursuant to the Separation and Distribution Agreement and shall transfer to the applicable Baxalta Local Entity on the relevant Local Closing
Date. 

  

	 	(b)	 The Parties hereby agree that the aggregate value of all trade accounts payable resulting from sales of Baxalta
Products or services prior to any Local Closing, whether resulting from sales or services prior to or after the Effective Time and whether owed to a Third Party, Baxter (or one of its Affiliates) or Baxalta (or one of

  
 2 

	 	
its Affiliates) (“Accounts Payable”) are intended to be Baxalta Liabilities pursuant to the Separation and Distribution Agreement and shall transfer to the applicable Baxalta
Local Entity on the relevant Local Closing Date. 

  

	 	(c)	Prior to the relevant Local Closing Date, Accounts Receivable owed by Baxter (or one of its Affiliates) or Accounts Payable owed to Baxter (or one of its Affiliates) or Baxalta (or one of its Affiliates) shall be
settled in the normal course of business under current customary terms that apply to non-intercompany trade payables and receivables by each Baxter Local Entity and in the event that any such Accounts Receivables or Accounts Payables are unable to
be settled in full or in part as a result of foreign currency control restrictions, such Accounts Receivables or Accounts Payables shall remain outstanding and shall transfer to the applicable Baxalta Local Entity on the relevant Local Closing Date.

  

	4.	Payment Terms. The Parties hereby agree that, to the extent not otherwise addressed in the Separation and Distribution Agreement, an Ancillary Agreement or a Conveyance and Assumption Instrument, all
payments to be made from one Party (or one of its Affiliates) (the “Remitting Party”) to the other Party (or one of its Affiliates) (the “Non-Remitting Party”) in connection with the Separation shall be made no
later than sixty (60) days following the date upon which (i) the Non-Remitting Party pays an amount to a Third Party on behalf of the Remitting Party or (ii) the Remitting Party receives an amount from a Third Party on behalf of the
Non-Remitting Party. 

  

	5.	Incorporation by Reference. Article IX (other than Section 9.02) of the Separation and Distribution Agreement is hereby incorporated into this Agreement by reference and made applicable to the
Parties hereto in such manner as the context requires in order to give effect to such provisions within this Agreement. 

  

	6.	Governing Law. This Agreement shall be governed by and construed and interpreted in accordance with the Laws of the State of Delaware, irrespective of the choice of Laws and principles of the State of
Delaware, as to all matters, including matters of validity, construction, effect, enforceability, performance and remedies. 

* * * * * 

  
 3 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives. 
  

			
	BAXTER INTERNATIONAL INC.
		
	By:	 	 /s/ James K. Saccaro

	Name:	 	James K. Saccaro
	Title:	 	Corporate Vice President and Chief Financial Officer
		 	(duly authorized officer and principal financial officer)
	
	BAXALTA INCORPORATED
		
	By:	 	 /s/ Robert J. Hombach

	Name:	 	Robert J. Hombach
	Title:	 	Executive Vice President, Chief Financial Officer and Chief Operations Officers
		 	(duly authorized officer and principal financial officer)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]